PSYCHEDELIC DRUGS SHOWN TO PROMOTE NEURAL PLASTICITY
Psychedelic drugs have amazing consciousness altering features. Specifically LSD(Acid), Magic Mushrooms (Psilocybin), MDMA (whose research is sponsored by MAPS.org ) as explained by MAPS founder Rick Doblin and DMT (Dimethyltryptamine used in Ayahuasca by Amazonian Shamans) have the potential to change brain’s nueral wiring.
With psychedelic use, the neurons are more likely to reach out and link with each other, forming new neural pathways that never existed before.
PSYCHEDELICS AND NEUROPLASTICITY
As published in the journal Cell Reports Ly et al. Psychedelics Promote Structural and Functional Neural Plasticity. Cell Reports, 2018 DOI: 10.1016/j.celrep.2018.05.022, this supports the theory that psychedelics may help fight anxiety, post-traumatic stress disorder, and depressive disorders as well as ADD, ADHD, and OCD.
PSYCHEDELICS AND DEPRESSION
Depression is often thought to stem from imbalanced brain chemistry, however, psychedelic research shows that it could also have to do with the lack of stimulation a brain recieves. Brains which are more stimulated by various kinds of experiences develop new neural pathways to help cope with the situations they might go through.
SCIENTISTS DISCOVER NEURONAL EFFECTS OF PSYCHEDELIC DRUGS
Evidence has been showcased by recent scientific studies that depression takes form as structural change within the circuitry of the brain. Depression is sometimes a result of atrophy in particular parts of the brain. Neurons become stagnant, which is that neurites shrivel and fail to form new neural connections. Using psychedelics for neuroplasticity yeilds positive results.
The neuron has parts called neutrites which connect the gaps in between neurons at the synaptic level to promote neurochemical communication. Characteristic of depression is that prefrontal cortex neurites often shrivel up. These changes also appear in cases associated with post-traumatic stress disorder, panic, and addiction.
Psychedelics from ergoline (Lysergamides such as LSD, 1P-LSD, ETH-LAD, ALD-52, AL-LAD, and 1P-ETH-LAD), amphetamines (such as MDMA), and tryptamine drug classes (such as Psilocybin and DMT) were examined in this study within both animal and test tube experiments.
PSYCHEDELICS PROMOTE STRUCTURAL AND FUNCTIONAL NEURAL PLASTICITY
Structual and functional changes by some of these particular psychedelics have shown results similar to those seen in ketamine studies. They grow the density of dendritic spines and synapses in the cortical neurons.
LSD had been experimentally shown to be a lot more effective and potent than ketamine in advancing neurite growth.
Psychedelics may not be ready for psychiatric prescriptions anytime soon, but they do a great deal to help with depressive disorders. Psychedelics for neuroplasticity should be studied more.